Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVERS.L Regulatory News (VERS)

  • There is currently no data for VERS

Director/PDMR Shareholding

21 Sep 2016 07:00

RNS Number : 3824K
Verseon Corporation
21 September 2016
 

For immediate release

21 September 2016

 

 

Verseon Corporation

("Verseon" or the "Company")

 

Director/PDMR Shareholding

 

Verseon, a technology-based pharmaceutical company, has received notification that Eniko Fodor, the Chief Operating Officer and Chief Financial Officer of the Company, has purchased 6,000 common shares of par value $0.001 each in the Company ("Common Shares") at a purchase price of £1.61 per Common Share.

 

Following the purchase, Ms. Fodor will hold 31,008,486 Common Shares, representing approximately 20.5% of the Company's issued share capital.

 

 

For further information please contact:

 

Verseon Corporation

+1 (510) 225 9000

Arthur Shmurun / Amy Thai

Cenkos Securities (NOMAD and Broker)

+44 (0) 20 7397 8900

Mark Connelly / Steve Cox

Buchanan Communications Ltd (PR Advisers)

+44 (0) 20 7466 5000

Henry Harrison-Topham / Sophie Cowles

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Eniko Fodor

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director and Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Verseon Corporation

b)

 

LEI

 

 

N/a

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Common Shares of par value $0.001

 

 

ISIN: USU9221J1098

b)

 

Nature of the transaction

 

 

Purchase of Common Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£1.61

 

6,000

 

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

6,000

 

 

£1.61

 

e)

 

Date of the transaction

 

 

19 September 2016

f)

 

Place of the transaction

 

 

N/a

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBBLLLQKFXBBD
Date   Source Headline
24th Oct 20187:00 amRNSAnnouncement of 2018 Annual General Meeting
11th Oct 20187:00 amRNSBlockchain agreement with Neuseren
1st Oct 20188:59 amRNSAdditional Listing & Total Voting Rights
18th Sep 20187:00 amRNSVerseon unveils new blockchain technology
13th Sep 20187:00 amRNSVerseon commences anticoagulant phase I trial
31st Aug 20187:00 amRNSAdditional Listing & Total Voting Rights
16th Aug 20187:00 amRNSChange of Adviser
8th Aug 20187:00 amRNSInterim Results
18th Jul 20187:00 amRNSVerseon submits phase I protocol for VE-1902
6th Jul 20187:00 amRNSAdditional Listing & Total Voting Rights
2nd Jul 20187:00 amRNSAdditional Listing & Total Voting Rights
25th Jun 20187:00 amRNSFinal Results
14th Jun 20187:00 amRNSVerseon preparing for anticoagulant phase I trial
13th Jun 20187:03 amRNSVerseon closes US$ 22.7M mortgage
12th Jun 20187:00 amRNSAdditional Listing & Total Voting Rights
7th Jun 20187:00 amRNSVerseon presents anticoagulants at BIO 2018
2nd May 20187:00 amRNSVerseon presents DME efficacy data at ARVO 2018
18th Apr 20187:00 amRNSVerseon presents anticancer agents at AACR 2018
3rd Apr 20187:00 amRNSAdditional Listing & Total Voting Rights
5th Mar 20187:00 amRNSAdditional Listing & Total Voting Rights
10th Jan 20187:00 amRNSVerseon presents HAE program at Biotech Showcase
2nd Jan 20187:00 amRNSAdditional Listing & Total Voting Rights
15th Nov 20177:00 amRNSVerseon presents second anticoagulant candidate
14th Nov 20177:00 amRNSAdditional Listing & Total Voting Rights
8th Nov 20177:00 amRNSVerseon presents anticancer agents at BIO-Europe
8th Nov 20177:00 amRNSAdditional Listing & Total Voting Rights
20th Oct 20177:00 amRNSResult of Special Meeting & Board Appointment
2nd Oct 20177:00 amRNSVerseon presents new DME efficacy results
25th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSSpecial Shareholder Meeting & Change of Directors
22nd Sep 20177:00 amRNSVerseon closes PACE financing for its new facility
7th Aug 20177:00 amRNSAdditional Listing and Total Voting Rights
26th Jun 20177:00 amRNSVerseon presents data on DME program at BIO 2017
12th Jun 20177:00 amRNSVerseon to present drug programs at BIO 2017
6th Jun 20178:15 amRNSTransaction in Own Shares and Total Voting Rights
2nd May 20177:00 amRNSAdditional Listing & Total Voting Rights
26th Apr 20177:00 amRNSTR-1 Notification of Major Interest in Shares
26th Apr 20177:00 amRNSResult of 2017 Annual General Meeting
3rd Apr 20177:00 amRNSAnnouncement of 2017 Annual General Meeting
30th Mar 20177:00 amRNSVerseon to present anticoagulants at ACS 2017
20th Mar 20177:00 amRNSBIO-Europe Spring: Verseon presents anticoagulants
13th Mar 20177:00 amRNSFinal Results
30th Jan 20177:00 amRNSAdditional Listing & Total Voting Rights
4th Jan 20177:00 amRNSVerseon granted US patents for its inhibitors
6th Dec 20167:00 amRNSLower bleeding risk of Verseon anticoagulants
23rd Nov 20167:03 amRNSVerseon anticoagulants preserve platelet function
16th Nov 20167:00 amRNSAdditional Listing & Total Voting Rights
14th Nov 20167:00 amRNSNew anticoagulant data to be presented at AHA 2016
7th Nov 20167:00 amRNSAppointment of Corporate Brokers
31st Oct 20167:00 amRNSAdditional Listing & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.